Hepatoblastoma

Signs and symptoms

Patients are usually asymptomatic at diagnosis. As a result, disease is often advanced at diagnosis.

Pathophysiology

Hepatoblastomas originate from immature liver precursor cells, are typically unifocal, affect the right lobe of the liver more often than the left lobe, and can metastasize. They are categorized into two types: "Epithelial Type" and "Mixed Epithelial / Mesenchymal Type."

Individuals with familial adenomatous polyposis (FAP), a syndrome of early-onset colonic polyps and adenocarcinoma, frequently develop hepatoblastomas. Also, beta-catenin mutations have been shown to be common in sporadic hepatoblastomas, occurring in as many as 67% of patients.

Recently, other components of the Wnt signaling pathway have also demonstrated a likely role in constitutive activation of this pathway in the causation of hepatoblastoma. Accumulating evidence suggests that hepatoblastoma is derived from a pluripotent stem cell.

Syndromes with an increased incidence of hepatoblastoma include Beckwith–Wiedemann syndrome, Edward Syndrome, Down Syndrome, Aicardi syndrome, Li–Fraumeni syndrome, Goldenhar syndrome, von Gierke disease, and familial adenomatous polyposis.

Diagnosis

The most common method of testing for hepatoblastoma is a blood test checking the alpha-fetoprotein level. Alpha-fetoprotein (AFP) is used as a biomarker to help determine the presence of liver cancer in children. At birth, infants have relatively high levels of AFP, which fall to normal adult levels by the second year of life. The normal level for AFP in children has been reported as lower than 50 nanograms per milliliter (ng/ml) and 10 ng/ml in adults. An AFP level greater than 500 ng/ml is a significant indicator of hepatoblastoma. AFP is also used as an indicator of treatment success. If treatments are successful in removing the cancer, the AFP level is expected to return to normal.

Treatment

Surgical removal of the tumor, neoadjuvant chemotherapy prior to tumor removal, and liver transplantation have been used to treat these cancers. Primary liver transplantation provides high, long term, disease-free survival rate in the range of 80%, in cases of complete tumor removal and adjuvant chemotherapy survival rates approach 100%. The presence of metastases is the strongest predictor of a poor prognosis.

References

References

1. (December 2016). "Archived copy".
2. (March 2008). "Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: the SIOPEL group experience". European Journal of Cancer.
3. Willert, Jennifer. "Pediatric Hepatoblastoma Clinical Presentation: History, Physical, Causes".
4. Sternberg, Stephen. (2012). "Sternberg's diagnostic surgical pathology". LWW.
5. (August 2005). "The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds". The Journal of Pediatrics.
6. (November 2006). "Familial adenomatous polyposis in two brothers with hepatoblastoma: implications for diagnosis and screening". Pediatric Blood & Cancer.
7. (June 2000). "Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam". Cancer Research.
8. (July 2005). "Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver". Gastroenterology.
9. (June 2005). "Elevated expression of Wnt antagonists is a common event in hepatoblastomas". Clinical Cancer Research.
10. (November 2002). "Stem-like cells in hepatoblastoma". Medical and Pediatric Oncology.
11. Zimmerman A, Saxena R. Hepatoblastoma. In: WHO Classification of Tumours of the Digestive System, 4th, Bosman FT, Carneiro F, Hruban RH, Theise ND (Eds), IARC, Lyon 2010. p.229.
12. (August 2002). "A novel site on gamma 3 subunits important for assembly of GABA(A) receptors". The Journal of Biological Chemistry.
13. (February 2007). "Treatment outcomes for hepatoblastoma: an institution's experience over two decades". Pediatric Surgery International.
14. (January 2004). "Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience". Pediatric Blood & Cancer.
15. {{EMedicine. article. 986802. Pediatric Hepatoblastoma
16. (October 2005). "Liver transplantation for hepatoblastoma: indications and contraindications in the modern era". Pediatric Transplantation.
17. (June 2002). "Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group". Journal of Clinical Oncology.